Ironshore Pharmaceuticals Inc. is a pharmaceutical company whose mission is to commercialize innovative, patient-centric treatment options to improve the lives of patients and caregivers. Based in North Carolina, Ironshore Pharmaceuticals Inc. is responsible for the sales, marketing and distribution of pharmaceutical products within the US.
Ironshore Pharmaceuticals & Development, Inc., based in Grand Cayman, develops novel therapeutics by leveraging its proprietary drug-delivery technology, DELEXIS. Ironshore Pharmaceuticals Inc. and Ironshore Pharmaceuticals & Development, Inc. are both wholly owned subsidiaries of Highland Therapeutics, Inc. based in Toronto.
Ironshore Pharmaceuticals & Development, Inc., based in Grand Cayman, develops novel therapeutics by leveraging its proprietary drug-delivery technology, DELEXIS. Ironshore Pharmaceuticals Inc. and Ironshore Pharmaceuticals & Development, Inc. are both wholly owned subsidiaries of Highland Therapeutics, Inc. based in Toronto.
Services
Ironshore Pharmaceuticals Inc. is a US-based pharmaceutical company whose mission is to commercialize innovative, patient-centric treatment options to improve the lives of patients and caregivers. Based in Morrisville, North Carolina, Ironshore Pharmaceuticals Inc. is responsible for the sales, marketing and distribution of pharmaceutical products within the US.
Ironshore Pharmaceuticals & Development, Inc. is a pharmaceutical company whose mission is to develop innovative, patient-centric treatment options, utilizing the proprietary DELEXIS technology to improve the lives of patients and caregivers.
Based in Grand Cayman, Ironshore Pharmaceuticals & Development, Inc. is responsible for managing all intellectual property, and directing all research, development and manufacturing activities for its drug candidates.Ironshore Pharmaceuticals & Development, Inc. is a wholly owned subsidiary of Toronto-based Highland Therapeutics Inc.
Based in Grand Cayman, Ironshore Pharmaceuticals & Development, Inc. is responsible for managing all intellectual property, and directing all research, development and manufacturing activities for its drug candidates.Ironshore Pharmaceuticals & Development, Inc. is a wholly owned subsidiary of Toronto-based Highland Therapeutics Inc.
At Highland Therapeutics we invest in proprietary drug-delivery technologies to develop improved versions of existing drug products. Highland Therapeutics is the parent company of two wholly owned subsidiaries: Ironshore Pharmaceuticals & Development, Inc. based in the Cayman Islands and Ironshore Pharmaceutics Inc. based in the United States.
JORNAY PM is a novel formulation of methylphenidate leveraging the DELEXIS technology. The first and only stimulant dosed in the evening, JORNAY PM has demonstrated improvement in ADHD symptoms when the patient awakens the next morning and throughout the rest of the day. JORNAY PM is a federally controlled substance (CII) because it contains methylphenidate, which can be a target for people who abuse prescription medicines or street drugs.
The norms generated by this study can guide clinicians in the use of the BSFQ and PREMB-R for identifying those ADHD youth who may be experiencing difficulties in the early morning and late afternoon/evening. Such tools are needed given the availability of treatments that can target ADHD symptoms and impairments at these extremes of the daily routine.
Reviews
Be the first to review Ironshore Pharmaceuticals.
Write a Review
